How a new digital platform made CannBioRex's science legible to the people who fund it
Project:
the project
A digital platform to connect breakthrough science with the capital behind it
CannBioRex Pharmaceuticals develops synthetic, pharmaceutical-grade cannabinoids for unmet medical needs, backed by research teams at the Kennedy Institute (Oxford University) and Hebrew University. Its science is advanced. Yet, its website was a static set of pages that could not carry the weight of that science.
The cost of that gap was real. Investors could not get a clear read on the pipeline, the market opportunity, or the financial story. Researchers and potential partners could not see the expertise or find a path to collaborate. And the science stayed locked behind technical language, so non-experts missed why any of it mattered. When a company this innovative cannot explain itself online, investor interest wanes, and collaboration opportunities slip away.
CannBioRex partnered with Lazarev.agency to build a real digital platform: a single, credible hub explaining what the company is building, who is behind it, and why it matters commercially, without watering down the science.
The Project’s
Discovery Phase
A homepage to route every audience to its own path
A single homepage had to serve investors, researchers, and the public. When everyone shares one path, each group has to dig past content written for someone else.
We organized the CannBioRex platform around who is visiting, so each audience opens into the depth it expects. Investors reach the full financial story in one move, from company news to share structure and analyst coverage. The people CannBioRex most wants to reach land on a route shaped for them and stay long enough to engage.
A market-comparison section designed to build the case for capital
Our team built a market section into the CannBioRex platform to set the company against the wider field, comparing the players who matter on the terms investors weigh. Seeing where CannBioRex sits, and where the open ground is, turns a promising pipeline into a case for capital. Investors leave with the context to judge the opportunity for themselves and a reason to take the conversation further.
A news feed and downloadable materials to keep investors close
Interest cools when a company goes quiet or when the people sold on it cannot bring the story back to their own decision-makers.
We gave the CannBioRex platform a running news feed, share-performance tracking, and downloadable investor materials. An investor can track performance over time, opt into alerts, and leave with a corporate presentation and fact sheet to make the case internally.
A conversion-focused contact section to catch inbound at its warmest
Someone convinced by the science will move on if reaching the company takes effort, and that lost message is often a serious investor or partner.
We designed a contact section built for that moment: a short form, a newsletter opt-in, and a clear picture of where the company sits. Anyone ready to talk can start the conversation in seconds and choose to stay on the list even if the timing is not yet right.
AI & ML
Lazarev. agency offers comprehensive digital design services. Discover our range of related expertise supported by impactful case studies.
More Startups Cases
FAQ
What does an investor-ready biotech platform need to include?
Enough for a capital provider to judge the opportunity without chasing information elsewhere: the pipeline, the market context, the team's credentials, current performance, and take-away materials they can bring to their own decision-makers. On the CannBioRex platform, Lazarev.agency pulled the financial story, market position, and downloadable investor documents into one clear path, so a serious investor can move from curiosity to conversation in a few clicks.
How do you communicate complex science online without diluting it or losing non-experts?
Lead with why the work matters, then let the depth sit one layer down for the people who want it. Accessible language and a clear hierarchy carry the commercial relevance to investors and the public, while credentials and research detail hold up for specialists. CannBioRex's platform does both, so no audience is talked down to and none is shut out.
What is a weak or generic platform costing a biotech in investor interest?
More than most founders assume. When the science is hard to parse or the financial story is scattered, a capital provider moves on before engaging, and that lost visit is often exactly the investor or partner you wanted. The cost is invisible because it shows up as inbound that never arrives and conversations that never start. CannBioRex faced that gap: advanced science underserved by a site that could not carry it. Lazarev.agency closed it by reshaping the platform around the decisions investors and partners are trying to make, so the innovation stops being underplayed and starts pulling the right people toward a conversation.
How do you design one platform for investors, researchers, and the public without diluting the message?
Segment by audience, keep each route clear, and let every group reach its own material without wading through the rest. CannBioRex's platform guides each visitor to content shaped for them, which lowers the effort of finding what matters and keeps the people you most want to reach engaged longer.
How does a platform actually support an investor's decision?
By making the company easy to evaluate: market data, research focus, performance, and partnership potential presented in a comparable, well-organized form. On the CannBioRex platform, charts, updates, and concise summaries let an investor grasp the market position and see why the company earns a closer look.
Does mobile really matter for a biotech or pharma investor audience?
Yes. Investors and partners often form a first impression on a phone, between meetings and on the move. A responsive experience means leadership, research, and market content hold their structure and readability on any device, so a strong first impression is not lost to a broken layout.
How do you keep investors and partners engaged after the first visit?
Stay present and give advocates something to carry forward. CannBioRex's platform keeps news, performance, and investor materials current and easy to reach, so stakeholders return and bring the story into their own rooms. Consistent updates and financial transparency build the trust that keeps a conversation alive over time.
Hit me up! Let’s chat about your growth
